• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Current guidelines on prevention with a focus on dyslipidemias.以血脂异常为重点的现行预防指南。
Cardiovasc Diagn Ther. 2017 Apr;7(Suppl 1):S4-S10. doi: 10.21037/cdt.2017.04.04.
2
Management of Dyslipidemias in Europe and the USA: Same Evidence, Different Conclusions? Can We Find Common Ground?欧美血脂异常的管理:证据相同,结论不同?我们能找到共同点吗?
Curr Cardiol Rep. 2017 Jun;19(6):49. doi: 10.1007/s11886-017-0857-7.
3
How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.欧洲心脏病学会/欧洲动脉粥样硬化学会(ESC/EAS)和2013年美国心脏病学会/美国心脏协会(ACC/AHA)血脂异常治疗指南的效果如何?来自一家血脂诊所的经验教训。
Curr Med Res Opin. 2015 Feb;31(2):221-8. doi: 10.1185/03007995.2014.982751. Epub 2014 Nov 24.
4
New Recommendations and Revised Concepts in Recent Guidelines on the Management of Dyslipidemias to Prevent Cardiovascular Disease: the 2018 ACC/AHA and 2019 ESC/EAS Guidelines.新版血脂异常管理指南以预防心血管疾病:2018 年美国心脏病学会/美国心脏协会与 2019 年欧洲心脏病学会/欧洲动脉粥样硬化学会指南中的新建议和新概念。
Curr Cardiol Rep. 2020 Jul 9;22(9):87. doi: 10.1007/s11886-020-01331-z.
5
Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.ACC/AHA 与 ESC/EAS LDL-C 推荐对 ASCVD 残余风险降低的影响:来自 DAVINCI 的模拟研究。
Cardiovasc Drugs Ther. 2023 Oct;37(5):941-953. doi: 10.1007/s10557-022-07343-x. Epub 2022 May 14.
6
Primary prevention with statins in cardiovascular diseases: A Saudi Arabian perspective.沙特阿拉伯视角下他汀类药物在心血管疾病中的一级预防
J Saudi Heart Assoc. 2015 Jul;27(3):179-91. doi: 10.1016/j.jsha.2014.09.004. Epub 2014 Sep 28.
7
CAD Severity on Cardiac CTA Identifies Patients With Most Benefit of Treating LDL-Cholesterol to ACC/AHA and ESC/EAS Targets.心脏 CT 血管造影术的 CAD 严重程度确定了 LDL-胆固醇治疗获益最大的患者,符合 ACC/AHA 和 ESC/EAS 目标。
JACC Cardiovasc Imaging. 2020 Sep;13(9):1961-1972. doi: 10.1016/j.jcmg.2020.03.017. Epub 2020 Jun 17.
8
Comparison of ACC/AHA and ESC Guideline Recommendations Following Trial Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: Results From the Population-Based Rotterdam Study.比较 ACC/AHA 和 ESC 指南建议,基于临床试验证据,在心血管疾病一级预防中使用他汀类药物:来自基于人群的鹿特丹研究的结果。
JAMA Cardiol. 2016 Sep 1;1(6):708-13. doi: 10.1001/jamacardio.2016.1577.
9
Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan.2013年美国心脏病学会/美国心脏协会(ACC/AHA)胆固醇管理指南发布后两年内,美国一项大型医保计划中他汀类药物的起始使用模式
J Am Heart Assoc. 2017 May 4;6(5):e005205. doi: 10.1161/JAHA.116.005205.
10
Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States.东欧和美国胆固醇指南差异的人群效应。
JAMA Cardiol. 2016 Sep 1;1(6):700-7. doi: 10.1001/jamacardio.2016.1585.

引用本文的文献

1
Targeting fatty acid synthase reduces aortic atherosclerosis and inflammation.靶向脂肪酸合酶可减轻主动脉粥样硬化和炎症。
Commun Biol. 2025 Feb 19;8(1):262. doi: 10.1038/s42003-025-07656-1.
2
Association between the PLTP rs4810479 SNP and Serum Lipid Traits in the Chinese Maonan and Han Populations.PLTP rs4810479 单核苷酸多态性与中国毛南族和汉族人群血清脂质特征的关联。
Genet Res (Camb). 2021 Jul 2;2021:9925272. doi: 10.1155/2021/9925272. eCollection 2021.
3
Therapeutic effects of statins on chromosomal DNA damage of dyslipidemic patients.他汀类药物对血脂异常患者染色体 DNA 损伤的治疗作用。
Exp Biol Med (Maywood). 2019 Oct;244(13):1089-1095. doi: 10.1177/1535370219871895. Epub 2019 Aug 19.
4
Attenuation of atherogenic apo B-48-dependent hyperlipidemia and high density lipoprotein remodeling induced by vitamin C and E combination and their beneficial effect on lethal ischemic heart disease in mice.维生素 C 和 E 联合对载脂蛋白 B-48 依赖性高脂血症和高密度脂蛋白重构的抑制作用及其对小鼠致死性缺血性心脏病的有益作用。
Biol Res. 2018 Sep 15;51(1):34. doi: 10.1186/s40659-018-0183-6.
5
MDG-1, a Potential Regulator of PPARα and PPARγ, Ameliorates Dyslipidemia in Mice.MDG-1是PPARα和PPARγ的潜在调节因子,可改善小鼠血脂异常。
Int J Mol Sci. 2017 Sep 8;18(9):1930. doi: 10.3390/ijms18091930.

本文引用的文献

1
ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study.在非糖尿病欧洲人中,美国心脏病学会/美国心脏协会(ACC/AHA)关于他汀类药物一级预防的指南优于欧洲心脏病学会/欧洲动脉粥样硬化学会(ESC/EAS)指南:哥本哈根普通人群研究。
Eur Heart J. 2017 Feb 21;38(8):586-594. doi: 10.1093/eurheartj/ehw426.
2
Overview of guidelines for the management of dyslipidemia: EU perspectives.血脂异常管理指南概述:欧盟视角
Vasc Health Risk Manag. 2016 Sep 6;12:357-369. doi: 10.2147/VHRM.S89038. eCollection 2016.
3
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.2016年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南。
Eur Heart J. 2016 Oct 14;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272. Epub 2016 Aug 27.
4
Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States.东欧和美国胆固醇指南差异的人群效应。
JAMA Cardiol. 2016 Sep 1;1(6):700-7. doi: 10.1001/jamacardio.2016.1585.
5
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).2016年欧洲临床实践心血管疾病预防指南:欧洲心脏病学会和其他学会关于临床实践心血管疾病预防的第六联合工作组(由10个学会的代表和特邀专家组成)由欧洲心血管预防与康复协会(EACPR)特别贡献制定。
Eur Heart J. 2016 Aug 1;37(29):2315-2381. doi: 10.1093/eurheartj/ehw106. Epub 2016 May 23.
6
Lower might be better - It matters how you get there, and in whom.越低越好——关键在于你如何实现这一点,以及这涉及到谁。
Eur Heart J. 2016 May 1;37(17):1380-3. doi: 10.1093/eurheartj/ehw102. Epub 2016 Mar 29.
7
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.极低水平的致动脉粥样硬化脂蛋白与心血管事件风险:他汀类药物试验的荟萃分析。
J Am Coll Cardiol. 2014 Aug 5;64(5):485-94. doi: 10.1016/j.jacc.2014.02.615.
8
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.评价依折麦布联合辛伐他汀用于急性冠脉综合征后 18144 例患者的心血管事件减少作用: IMPROVE-IT 研究人群的最终基线特征。
Am Heart J. 2014 Aug;168(2):205-12.e1. doi: 10.1016/j.ahj.2014.05.004. Epub 2014 May 15.
9
The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.美国心脏病学会/美国心脏协会 2013 年成人治疗血胆固醇以降低动脉粥样硬化性心血管疾病风险指南:好的、坏的和不确定的:与 2011 年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南的比较。
Eur Heart J. 2014 Apr;35(15):960-8. doi: 10.1093/eurheartj/ehu107. Epub 2014 Mar 17.
10
Statins for millions more?他汀类药物惠及更多人?
Lancet. 2014 Feb 22;383(9918):669. doi: 10.1016/S0140-6736(14)60240-3.

以血脂异常为重点的现行预防指南。

Current guidelines on prevention with a focus on dyslipidemias.

作者信息

Graham Ian M, Catapano Alberico L, Wong Nathan D

机构信息

Trinity College Dublin, Dublin, Ireland.

Adelaide Health Foundation, Tallaght Hospital, Dublin, Ireland.

出版信息

Cardiovasc Diagn Ther. 2017 Apr;7(Suppl 1):S4-S10. doi: 10.21037/cdt.2017.04.04.

DOI:10.21037/cdt.2017.04.04
PMID:28529917
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5418212/
Abstract

Examination of the current the American College of Cardiology/American Heart Association (ACC/AHA) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines on the prevention of cardiovascular disease and the management of dyslipidemias finds much common ground. Both note that Atherosclerotic cardiovascular disease (ASCVD) is, in most people, the product of a number of risk factors, notably tobacco exposure, hyperlipidemia, hypertension, inactivity, overweight and diabetes. They stress that risk calculators can help in the assessment of risk in apparently healthy persons. Persons with established ASCVD and many with diabetes or renal impairment are at high to very high risk and warrant intensive risk factor advice and guideline-based preventive therapies. The ACC/AHA guidelines favor the universal use of statins in all high-risk subjects and in primary prevention where the global risk exceeds 7.5% in 10 years, with a percentage reduction in low-density lipoprotein cholesterol (LDL-C) based on statin intensity as the "goal". In contrast, the ESC/EAS guidelines favor a goal or percentage-based reduction in LDL-C based on total risk and baseline LDL-C level. Both guidelines consider certain imaging and other measures to stratify risk as well as the use of non-statin therapies in those not achieving recommended targets. Perhaps the most important challenges are to stress similarities rather than differences, and to simplify communications with both healthcare professionals and the public.

摘要

审视美国心脏病学会/美国心脏协会(ACC/AHA)以及欧洲心脏病学会/欧洲动脉粥样硬化协会(ESC/EAS)目前关于心血管疾病预防和血脂异常管理的指南,可以发现诸多共同点。两者均指出,在大多数人身上,动脉粥样硬化性心血管疾病(ASCVD)是多种危险因素共同作用的结果,尤其是烟草暴露、高脂血症、高血压、缺乏运动、超重和糖尿病。它们强调风险计算器有助于评估看似健康人群的风险。已确诊ASCVD的患者以及许多糖尿病或肾功能损害患者处于高风险至极高风险,需要强化风险因素建议以及基于指南的预防性治疗。ACC/AHA指南主张在所有高危人群以及10年全球风险超过7.5%的一级预防中普遍使用他汀类药物,以低密度脂蛋白胆固醇(LDL-C)降低百分比作为基于他汀强度的“目标”。相比之下,ESC/EAS指南主张基于总体风险和基线LDL-C水平,以LDL-C降低目标值或百分比为目标。两项指南均考虑采用某些影像学检查和其他措施对风险进行分层,以及在未达到推荐目标的人群中使用非他汀类疗法。或许最重要的挑战在于强调相似之处而非差异,并简化与医疗专业人员和公众的沟通。